Amgen (AMGN) valuation, revenue & earnings

P/E and P/S history, revenue and growth, ROIC vs. cost of capital, segments, earnings and analyst forecasts

At a glance

Market capitalisation$224B

Moat ratingNarrow moat

ValuationFair

Revenue, and where it comes from$36.8bn in 2025: general medicine and bone $11.6bn, inflammation and rare disease $11.0bn, oncology $6.7bn, established and other $4.4bn, biosimilars $3.0bn

Recent years are exact, taken from company filings; the earliest years are approximate. Forecast figures are Wall Street consensus, not company guidance. Read the full Amgen moat analysis →